Qiagen NV and Exosome Diagnostics Inc. have expanded their existing strategic partnership to develop a first-in-class, noninvasive molecular diagnostic for use in detecting and monitoring actionable genetic mutations in lung cancer patients.
Read MoreResearchers using the IsoFlux System have retrieved rare tumor cells from peripheral blood in early non-small cell lung cancer patients for molecular analysis. The study found that gross tumor volume positively correlated with CTC count.
Read More
The effort will evaluate Trovagene’s proprietary, urine-based, cell-free DNA technology for the detection of certain EGFR mutations associated with lung cancer.
Read More
The coverage decision means that more than 49 million eligible Medicare enrollees in the United States will now be able to benefit from VeriStrat being a covered diagnostic test, according to specific lung cancer indications outlined by Novitas.
Read More
Automated scans of FISH test slides of lung cancer cells preserve results, and enhance objectivity.
Read More